Global Neuromuscular Blocking Drugs Market

Neuromuscular Blocking Drugs Comprehensive Study by Distribution Channel (Online, Offline), End-User (Hospitals, Clinics, Others), Drug Class (Pachycurares, Leptocurares) Players and Region - Global Market Outlook to 2026

Neuromuscular Blocking Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Neuromuscular Blocking Drugs Market Scope
Neuromuscular blocking medications are powerful muscle relaxants that are used to restrict muscle movement and mechanical ventilation during surgery. Neuromuscular blocking medications usually act as both a pre-junctional and post-junctional receptor blocker. Neuromuscular blocking agents have a wide range of applications in hospitals, from surgery to trauma. The use of neuromuscular blocking drugs as an adjuvant in general anesthesia, electroshock therapy, endotracheal intubation, incubation and endoscopic operations, brief surgeries, and as adjuncts in the treatment of encephalitis, tetanus, and poliomyelitis is driving up demand for these drugs. The key reason driving the market's growth is the growing geriatric population, which is more prone to musculoskeletal problems. Other factors driving market expansion include the rising prevalence of pain and spasm problems, increased focus on the development of novel medications for the treatment of spasm and pain, frequent product approvals, and an increase in the number of surgeries.

The Neuromuscular Blocking Drugs market study is segmented and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Neuromuscular Blocking Drugs market throughout the predicted period.

Merck & Co., Inc. (United States), Hikma Pharmaceuticals (United States), GlaxoSmithKline Plc (United Kingdom), Abbott Laboratories (United States), AbbVie Inc. (United States), Pfizer (United States), Novartis AG (Switzerland), Bayer AG (Germany), Roche Inc (Switzerland) and Zydus Cadila (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Octagon Research Solutions (United States) and Aqua Pharmaceuticals (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Neuromuscular Blocking Drugs market by Type, Application and Region.

On the basis of geography, the market of Neuromuscular Blocking Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

June 2021 – FDA Approves Bridion to Reverse Effects of Neuromuscular Blocking Drugs Used During Surgery


Market Trend
  • Increasing Prevalence of Musculoskeletal Disorders

Market Drivers
  • Growing Geriatric Population

Opportunities
  • Increasing Research and Development Activities

Restraints
  • Stringent Regulatory Factors

Challenges
  • Harmful Effects of Ultraviolet Radiation and Increasing Prevalence of Skin Diseases


Key Target Audience
Drug Manufacturers and Suppliers, Academic Research Institutes, Hospitals and Clinics, Research and Development (R&D) Companies and Others

Report Objectives / Segmentation Covered

By Distribution Channel
  • Online
  • Offline

By End-User
  • Hospitals
  • Clinics
  • Others

By Drug Class
  • Pachycurares
  • Leptocurares

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Harmful Effects of Ultraviolet Radiation and Increasing Prevalence of Skin Diseases
    • 3.4. Market Trends
      • 3.4.1. Increasing Prevalence of Musculoskeletal Disorders
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neuromuscular Blocking Drugs, by Distribution Channel, End-User, Drug Class and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Neuromuscular Blocking Drugs (Value)
      • 5.2.1. Global Neuromuscular Blocking Drugs by: Distribution Channel (Value)
        • 5.2.1.1. Online
        • 5.2.1.2. Offline
      • 5.2.2. Global Neuromuscular Blocking Drugs by: End-User (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Neuromuscular Blocking Drugs by: Drug Class (Value)
        • 5.2.3.1. Pachycurares
        • 5.2.3.2. Leptocurares
      • 5.2.4. Global Neuromuscular Blocking Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Neuromuscular Blocking Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co., Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Hikma Pharmaceuticals (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AbbVie Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bayer AG (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Roche Inc (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Zydus Cadila (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Neuromuscular Blocking Drugs Sale, by Distribution Channel, End-User, Drug Class and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Neuromuscular Blocking Drugs (Value)
      • 7.2.1. Global Neuromuscular Blocking Drugs by: Distribution Channel (Value)
        • 7.2.1.1. Online
        • 7.2.1.2. Offline
      • 7.2.2. Global Neuromuscular Blocking Drugs by: End-User (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Neuromuscular Blocking Drugs by: Drug Class (Value)
        • 7.2.3.1. Pachycurares
        • 7.2.3.2. Leptocurares
      • 7.2.4. Global Neuromuscular Blocking Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neuromuscular Blocking Drugs: by Distribution Channel(USD Million)
  • Table 2. Neuromuscular Blocking Drugs Online , by Region USD Million (2015-2020)
  • Table 3. Neuromuscular Blocking Drugs Offline , by Region USD Million (2015-2020)
  • Table 4. Neuromuscular Blocking Drugs: by End-User(USD Million)
  • Table 5. Neuromuscular Blocking Drugs Hospitals , by Region USD Million (2015-2020)
  • Table 6. Neuromuscular Blocking Drugs Clinics , by Region USD Million (2015-2020)
  • Table 7. Neuromuscular Blocking Drugs Others , by Region USD Million (2015-2020)
  • Table 8. Neuromuscular Blocking Drugs: by Drug Class(USD Million)
  • Table 9. Neuromuscular Blocking Drugs Pachycurares , by Region USD Million (2015-2020)
  • Table 10. Neuromuscular Blocking Drugs Leptocurares , by Region USD Million (2015-2020)
  • Table 11. South America Neuromuscular Blocking Drugs, by Country USD Million (2015-2020)
  • Table 12. South America Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 13. South America Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 14. South America Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 15. Brazil Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 16. Brazil Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 17. Brazil Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 18. Argentina Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 19. Argentina Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 20. Argentina Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 21. Rest of South America Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 22. Rest of South America Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 23. Rest of South America Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 24. Asia Pacific Neuromuscular Blocking Drugs, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 26. Asia Pacific Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 27. Asia Pacific Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 28. China Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 29. China Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 30. China Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 31. Japan Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 32. Japan Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 33. Japan Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 34. India Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 35. India Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 36. India Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 37. South Korea Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 38. South Korea Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 39. South Korea Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 40. Taiwan Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 41. Taiwan Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 42. Taiwan Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 43. Australia Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 44. Australia Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 45. Australia Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 49. Europe Neuromuscular Blocking Drugs, by Country USD Million (2015-2020)
  • Table 50. Europe Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 51. Europe Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 52. Europe Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 53. Germany Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 54. Germany Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 55. Germany Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 56. France Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 57. France Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 58. France Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 59. Italy Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 60. Italy Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 61. Italy Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 62. United Kingdom Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 63. United Kingdom Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 64. United Kingdom Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 65. Netherlands Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 66. Netherlands Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 67. Netherlands Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 68. Rest of Europe Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 69. Rest of Europe Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 70. Rest of Europe Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 71. MEA Neuromuscular Blocking Drugs, by Country USD Million (2015-2020)
  • Table 72. MEA Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 73. MEA Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 74. MEA Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 75. Middle East Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 76. Middle East Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 77. Middle East Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 78. Africa Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 79. Africa Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 80. Africa Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 81. North America Neuromuscular Blocking Drugs, by Country USD Million (2015-2020)
  • Table 82. North America Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 83. North America Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 84. North America Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 85. United States Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 86. United States Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 87. United States Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 88. Canada Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 89. Canada Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 90. Canada Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 91. Mexico Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 92. Mexico Neuromuscular Blocking Drugs, by End-User USD Million (2015-2020)
  • Table 93. Mexico Neuromuscular Blocking Drugs, by Drug Class USD Million (2015-2020)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Neuromuscular Blocking Drugs: by Distribution Channel(USD Million)
  • Table 105. Neuromuscular Blocking Drugs Online , by Region USD Million (2021-2026)
  • Table 106. Neuromuscular Blocking Drugs Offline , by Region USD Million (2021-2026)
  • Table 107. Neuromuscular Blocking Drugs: by End-User(USD Million)
  • Table 108. Neuromuscular Blocking Drugs Hospitals , by Region USD Million (2021-2026)
  • Table 109. Neuromuscular Blocking Drugs Clinics , by Region USD Million (2021-2026)
  • Table 110. Neuromuscular Blocking Drugs Others , by Region USD Million (2021-2026)
  • Table 111. Neuromuscular Blocking Drugs: by Drug Class(USD Million)
  • Table 112. Neuromuscular Blocking Drugs Pachycurares , by Region USD Million (2021-2026)
  • Table 113. Neuromuscular Blocking Drugs Leptocurares , by Region USD Million (2021-2026)
  • Table 114. South America Neuromuscular Blocking Drugs, by Country USD Million (2021-2026)
  • Table 115. South America Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 116. South America Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 117. South America Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 118. Brazil Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 119. Brazil Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 120. Brazil Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 121. Argentina Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 122. Argentina Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 123. Argentina Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 124. Rest of South America Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 125. Rest of South America Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 126. Rest of South America Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 127. Asia Pacific Neuromuscular Blocking Drugs, by Country USD Million (2021-2026)
  • Table 128. Asia Pacific Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 129. Asia Pacific Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 130. Asia Pacific Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 131. China Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 132. China Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 133. China Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 134. Japan Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 135. Japan Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 136. Japan Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 137. India Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 138. India Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 139. India Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 140. South Korea Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 141. South Korea Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 142. South Korea Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 143. Taiwan Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 144. Taiwan Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 145. Taiwan Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 146. Australia Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 147. Australia Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 148. Australia Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 149. Rest of Asia-Pacific Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 152. Europe Neuromuscular Blocking Drugs, by Country USD Million (2021-2026)
  • Table 153. Europe Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 154. Europe Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 155. Europe Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 156. Germany Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 157. Germany Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 158. Germany Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 159. France Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 160. France Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 161. France Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 162. Italy Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 163. Italy Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 164. Italy Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 165. United Kingdom Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 166. United Kingdom Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 167. United Kingdom Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 168. Netherlands Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 169. Netherlands Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 170. Netherlands Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 171. Rest of Europe Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 172. Rest of Europe Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 173. Rest of Europe Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 174. MEA Neuromuscular Blocking Drugs, by Country USD Million (2021-2026)
  • Table 175. MEA Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 176. MEA Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 177. MEA Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 178. Middle East Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 179. Middle East Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 180. Middle East Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 181. Africa Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 182. Africa Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 183. Africa Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 184. North America Neuromuscular Blocking Drugs, by Country USD Million (2021-2026)
  • Table 185. North America Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 186. North America Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 187. North America Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 188. United States Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 189. United States Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 190. United States Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 191. Canada Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 192. Canada Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 193. Canada Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 194. Mexico Neuromuscular Blocking Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 195. Mexico Neuromuscular Blocking Drugs, by End-User USD Million (2021-2026)
  • Table 196. Mexico Neuromuscular Blocking Drugs, by Drug Class USD Million (2021-2026)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neuromuscular Blocking Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 5. Global Neuromuscular Blocking Drugs: by End-User USD Million (2015-2020)
  • Figure 6. Global Neuromuscular Blocking Drugs: by Drug Class USD Million (2015-2020)
  • Figure 7. South America Neuromuscular Blocking Drugs Share (%), by Country
  • Figure 8. Asia Pacific Neuromuscular Blocking Drugs Share (%), by Country
  • Figure 9. Europe Neuromuscular Blocking Drugs Share (%), by Country
  • Figure 10. MEA Neuromuscular Blocking Drugs Share (%), by Country
  • Figure 11. North America Neuromuscular Blocking Drugs Share (%), by Country
  • Figure 12. Global Neuromuscular Blocking Drugs share by Players 2020 (%)
  • Figure 13. Global Neuromuscular Blocking Drugs share by Players (Top 3) 2020(%)
  • Figure 14. Global Neuromuscular Blocking Drugs share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 18. Hikma Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 19. Hikma Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 20. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 22. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 23. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 24. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. AbbVie Inc. (United States) Revenue: by Geography 2020
  • Figure 26. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer (United States) Revenue: by Geography 2020
  • Figure 28. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 30. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 32. Roche Inc (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Roche Inc (Switzerland) Revenue: by Geography 2020
  • Figure 34. Zydus Cadila (India) Revenue, Net Income and Gross profit
  • Figure 35. Zydus Cadila (India) Revenue: by Geography 2020
  • Figure 36. Global Neuromuscular Blocking Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 37. Global Neuromuscular Blocking Drugs: by End-User USD Million (2021-2026)
  • Figure 38. Global Neuromuscular Blocking Drugs: by Drug Class USD Million (2021-2026)
  • Figure 39. South America Neuromuscular Blocking Drugs Share (%), by Country
  • Figure 40. Asia Pacific Neuromuscular Blocking Drugs Share (%), by Country
  • Figure 41. Europe Neuromuscular Blocking Drugs Share (%), by Country
  • Figure 42. MEA Neuromuscular Blocking Drugs Share (%), by Country
  • Figure 43. North America Neuromuscular Blocking Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck & Co., Inc. (United States)
  • Hikma Pharmaceuticals (United States)
  • GlaxoSmithKline Plc (United Kingdom)
  • Abbott Laboratories (United States)
  • AbbVie Inc. (United States)
  • Pfizer (United States)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Roche Inc (Switzerland)
  • Zydus Cadila (India)
Additional players considered in the study are as follows:
Octagon Research Solutions (United States) , Aqua Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


Jul 2021 208 Pages 88 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Neuromuscular Blocking Drugs Market Quantitative research analysis
Global Neuromuscular Blocking Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Know More About Global Neuromuscular Blocking Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Sarcopenia Supplement Comprehensive Study by Type (Protein Supplement, Vitamin D & Calcium Supplement, Vitamin B12 Supplement), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online ph...
$ 3500
The Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Comprehensive Study by CRO Service (Discovery, Preclinical, Clinical Service, Laboratory Service), CMO Service (Active Ph...
$ 3750
Roll Compactor Comprehensive Study by Type (• <30Kg/Hour, • 30 – 200Kg/Hour, • >200Kg/Hour), Sales Channel (Online, Offline), End User (Pharmaceutical, Food and Beverage, Chemical, Others) Players an...
$ 3500
VLP Vaccines Comprehensive Study by Virus (Covid-19, Zika, HIV, Adeno-Associated Virus, Hepatitis C), Form (Tablet, Injectables, Capsules, Others), End Use (Hospitals, Specialty Clinics), Vaccine (Li...
$ 3650
Antithyroid Drug Comprehensive Study by Type (Propylthiouracil, Methimazole), Application (Hospital, Specialty Clinics), Distribution Channels (Hospital Dispensary, Retail Pharmacy, Online Pharmacy) ...
$ 3500
Yacon Syrup Comprehensive Study by Type (Conventional, Organic), Application (Household, Commercial), Packaging (Bottle, Can, Pouches, Others), Sales Channel (Online, Offline) Players and Region - Gl...
$ 3500